Macedonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
hydroxamic acid/рак
Врската е зачувана во таблата со исечоци
Страница 1 од 37 резултати
Vorinostat (SAHA) in Uterine Sarcoma
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
This is an open-label, single arm, proof of concept-study of the HDAC-inhibitor vorinostat in patients with refractory uterine sarcoma that have been pre-tested for an high expression of HDAC. Patients will receive Vorinostat, 400 mg (4 capsules á 100mg of Zolinza) orally once daily for the first 14
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of lymphoproliferative disorder arising from mature T-cells of post-thymic origin. PTCL represent a relatively uncommon group of hematologic malignancies within non-Hodgkin lymphomas (NHL), accounting for about 10% of NHL cases. The
Evaluating Dietary Intervention Before surgicaL Treatment for Epilepsy
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Epilepsy surgery is now an accepted and effective management for individuals with drug resistant focal onset epilepsy in carefully selected candidates. This aside, only two RCTs have been performed in adults in temporal lobe epilepsy [1,2], and none in children . Malformations of cortical
Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
- A cohort of three patients will be treated at each dose level for one cycle (28 days per cycle).
- Treatment will be continued if no DLTs are recorded, and three patients will be treated at the next higher dose level.
- If a patient of the cohort develops a DLT, however, another cohort of three
Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
PRIMARY OBJECTIVES:
I. To evaluate the ability of histone deacetylase (HDAC) inhibition using suberoylanilide hydroxamic acid (SAHA) (vorinostat) to induce expression of the estrogen receptor (ER) and progesterone receptor (PR) genes in solid human triple negative invasive breast
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
In the United States, the incidence of acute myeloid leukemia (AML) is approximately 3.5 cases per 100,000 persons per year. Approximately 13,000 people were diagnosed with AML in 2009 and 9,000 died of the disease, making AML the 6th leading cause of cancer death. Over the past three decades, AML
Vorinostat in Children
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Relapsed or progressive solid tumors and leukemias have a very poor prognosis in children despite intense multimodal treatment protocols involving polychemotherapy, surgery, and radiation. Therefore, innovative treatment strategies targeting specific molecular mechanisms are urgently required. A
Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
PRIMARY OBJECTIVES:
I. To evaluate the efficacy by means of response rate (based on Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria) of vorinostat in the treatment of patients with locally advanced, recurrent or metastatic adenoid cystic carcinoma (ACC).
SECONDARY OBJECTIVES:
I.
LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
The combination of Carboplatin (C) and Paclitaxel (PTX) is considered standard treatment in patients with epithelial ovarian cancer and endometrial cancer, in USA and in those in whom anthracyclines are not recommended. In cervical cancer, where very often the renal function is impaired, C
Development and Exploration of the Feasibility of Using Locally Synthesized Small Molecule Inhibitors to Treat Human Acute Leukemia Cells
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Key eligibility criteria include:
- Newly diagnosed invasive breast cancer awaiting surgery or neoadjuvant (preoperative) treatment
- No use of hormone contraceptives or replacement therapy within 30 days prior to the diagnostic breast cancer biopsy (unless willing to have an additional biopsy prior
A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Background:
- New options for the treatment of patients with advanced thymoma and thymic carcinoma are needed.
- Belinostat, N-hydroxy-3-(phenylsulphamoylphenyl) acrylamide, is a hydroxamic acid deacetylase inhibitor that is able to inhibit both histone deacetylase inhibitors (HDAC) Class I and II
Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC)
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Phase I design
- Three patients will be treated per cohort for one cycle (28 days per cycle).
- If no DLTs are recorded, treatment will continue and three patients will be treated in the subsequent cohort.
- However, if a patient develops a DLT, another three patients will be treated in this cohort
Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
OBJECTIVES:
Primary
- To determine the efficacy of vorinostat (suberoylanilide hydroxamic acid, SAHA), when administered orally, in a pulsed fashion, once-a-day for 3 consecutive days every week, in inducing a 4% absolute increase or a 100% increase in fetal hemoglobin percent levels (HbF%) in
Најкомплетната база на податоци за лековити билки поддржана од науката
- Работи на 55 јазици
- Лекови од билки поддржани од науката
- Препознавање на билки по слика
- Интерактивна GPS мапа - означете ги билките на локацијата (наскоро)
- Прочитајте научни публикации поврзани со вашето пребарување
- Пребарувајте лековити билки според нивните ефекти
- Организирајте ги вашите интереси и останете во тек со истражувањето на новостите, клиничките испитувања и патентите
Напишете симптом или болест и прочитајте за билки што можат да помогнат, напишете билка и видете болести и симптоми против кои се користи.
* Сите информации се базираат на објавени научни истражувања
